
STAAR Surgical Company
NASDAQ•STAA
CEO: Mr. Thomas G. Frinzi
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 1992-02-24
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Contact Information
Market Cap
$1.19B
P/E (TTM)
-12.6
76.8
Dividend Yield
--
52W High
$30.81
52W Low
$13.50
52W Range
Rank39Top 29.7%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q4 2025 Data
Revenue
$94.73B+193428.09%
4-Quarter Trend
EPS
$179.40-26100.00%
4-Quarter Trend
FCF
$0.00-100.00%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Nine Month Sales Decline Net sales $181.6M, down 31.4% for nine months, driven by China distributor inventory normalization and payment timing.
Operating Performance Deterioration Nine months resulted in a Net Loss of ($62.1M), compared to $14.0M income prior year period.
Cash Position Strengthened Ending cash $176.2M, increased $32.0M over prior year, supported by strong investing cash flows.
Restructuring Charges Recognized Recognized $27.9M in restructuring and impairment charges during nine months related to workforce realignment efforts.
Risk Factors
Alcon Merger Uncertainty Merger completion subject to stockholder vote and regulatory approvals; facing opposition from Broadwood Group activism.
China Sales Volatility Risk Future sales depend on resolving China tariff situation and managing shift to smaller, frequent inventory purchases.
Significant Merger Transaction Costs Incurred $5.9M in professional service expenses for the Alcon merger during the quarter ended September 2025.
Outlook
China Inventory Strategy Shift Implementing consignment inventory in China to align distributor purchases closer to actual procedural volumes.
Merger Closing Conditions Focus remains on satisfying closing conditions, including stockholder adoption, for the proposed transaction with Alcon.
Cost Reduction Realignment Leadership realignment efforts substantially completed as of June 2025, aiming for sustainable profitable growth trajectory.
Peer Comparison
Revenue (TTM)
STAA$94.91B
$886.89M
$642.07M
Gross Margin (Latest Quarter)
STAA82.2%
ESTA70.1%
64.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ESTA | $2.11B | -25.9 | -253.8% | 0.9% |
| AZTA | $1.61B | -27.2 | -3.5% | 2.5% |
| TSHA | $1.52B | -20.5 | -67.3% | 5.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1205.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention
Research & Insights
Next earnings:Feb 10, 2026
EPS:$0.14
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 26, 2025|Filed: Nov 5, 2025|Revenue: $94.73M+6.9%|EPS: $0.18-10.0%MeetForm 10-Q - Q3 2025
Period End: Jun 27, 2025|Filed: Aug 6, 2025|Refer to amended dataForm 10-Q - Q1 2025
Period End: Mar 28, 2025|Filed: May 7, 2025|Revenue: $42.59M-44.9%|EPS: $-1.10+1510.5%MissForm 10-K - FY 2024
Period End: Dec 27, 2024|Filed: Feb 21, 2025|Revenue: $313.90M-2.6%|EPS: $-0.41-193.2%MissForm 10-Q - Q3 2024
Period End: Sep 27, 2024|Filed: Oct 30, 2024|Revenue: $88.59M+10.3%|EPS: $0.20+101.8%BeatForm 10-Q - Q2 2024
Period End: Jun 28, 2024|Filed: Aug 7, 2024|Revenue: $99.01M+7.3%|EPS: $0.15+15.4%MissForm 10-Q - Q1 2024
Period End: Mar 29, 2024|Filed: May 7, 2024|Revenue: $77.36M+5.2%|EPS: $-0.07-221.5%MissForm 10-K - FY 2023
Period End: Dec 29, 2023|Filed: Feb 27, 2024|Revenue: $322.42M+13.4%|EPS: $0.44-47.0%Beat